Dyax Corp. (Nasdaq: DYAX), which recently moved to Burlington from Cambridge, said it has granted Eclipse Therapeutics Inc. of San Diego an exclusive worldwide license to develop and commercialize preclinical fully-human antibodies using Dyax’s phage display technology for oncology indications.

SOURCE